Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP | P16109 | 8/20 | 0.58 |
| ▸ | FAAH | O00519 | 4/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.42 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1170902 | 0.92 | SELP (0.58) | SELPFAAH | |
| SCHEMBL1170900 | 0.92 | SELP (0.58) | SELPFAAH | |
| SCHEMBL1170905 | 0.92 | SELP (0.58) | SELPFAAH | |
| SCHEMBL1170783 | 0.90 | SELP (0.56) | SELPFAAH | |
| SCHEMBL1170786 | 0.90 | SELP (0.56) | SELPFAAH | |
| SCHEMBL1170785 | 0.90 | SELP (0.56) | SELPFAAH | |
| SCHEMBL1170975 | 0.89 | PTPN1 (0.50) | SELPFAAH | |
| SCHEMBL1170807 | 0.87 | SELP (0.53) | SELPFAAH | |
| SCHEMBL1170806 | 0.87 | SELP (0.53) | SELPFAAH | |
| SCHEMBL1170808 | 0.87 | SELP (0.53) | SELPFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211859-B2 | α-galactoceramide analogs, their methods of manufacture, intermediate compounds useful in these methods, and pharmaceutical compositions containing them | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-07-03 | — | — | US | disclosed |
| US-20110028411-A1 | ALPHA-GALACTOCERAMIDE ANALOGS, THEIR METHODS OF MANUFACTURE, INTERMEDIATE COMPOUNDS USEFUL IN THESE METHODS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFQUE (FR) | 2011-02-03 | — | — | US | disclosed |
| WO-2008047249-A9 | ALPHA-GALACTOCERAMIDE ANALOGS, THEIR METHODS OF MANUFACTURE, INTERMEDIATE COMPOUNDS USEFUL IN THESE METHODS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2009-12-23 | — | — | WO | disclosed |
| EP-2099813-A2 | ALPHA-GALACTOCERAMIDE ANALOGS, THEIR METHODS OF MANUFACTURE, INTERMEDIATE COMPOUNDS USEFUL IN THESE METHODS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Centre National de la Recherche Scientifique (FR) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008047249-A2 | ALPHA-GALACTOCERAMIDE ANALOGS, THEIR METHODS OF MANUFACTURE, INTERMEDIATE COMPOUNDS USEFUL IN THESE METHODS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028411-A1 | ALPHA-GALACTOCERAMIDE ANALOGS, THEIR METHODS OF MANUFACTURE, INTERMEDIATE COMPOUNDS USEFUL IN THESE METHODS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GALE, GALNT14, GALC | SELP 4550/4885FAAH 480/4885EPHX2 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.